afatinib (BIBW 2992)

DRUG2 trials

Sponsors

Boehringer Ingelheim, University College, London

Conditions

Carcinoma, Non-Small-Cell Lung

Phase 2

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

CompletedNCT01003899

Boehringer IngelheimCarcinoma, Non-Small-Cell Lung

Start: 2009-10-31Updated: 2013-12-31

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

CompletedNCT01415011

University College, LondonCarcinoma, Non-Small-Cell Lung

Start: 2012-12-31End: 2018-11-30Updated: 2019-01-15

Related Papers

Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy

British Journal of Cancer2024-12-051 citations